Effective lipid-lowering therapy (LLT) reduces the risk of cardiovascular outcomes in patients at high cardiovascular risk, as well as in those without a history of myocardial infarction (MI) or stroke. The VESALIUS-CV trial demonstrated the benefit of intensive low-density lipoprotein cholesterol (LDL-C) lowerin...
Q. Chan, J. Cegla, J. Cornel et al.· European Heart Journal· 0 citations
In this large, global, real-world study, most patients with CAD at risk of a first MACE were undertreated with LLT and did not achieve recommended LDL-C levels, highlighting substantial gaps between guideline recommendations and real-world practice.
Q. Chan, J. Cegla, J. Cornel et al.· European Heart Journal· 0 citations
Most patients at high CV risk were not optimally managed, with low rates of LLT initiation, treatment intensification, LDL-C monitoring, and LDL-C goal attainment across 11 databases, highlighting a substantial unmet clinical need for improved guideline-based lipid management to prevent first major CV events in high-ri...
Q. Chan, J. Cegla, U. Laufs et al.· Clinical Research in Cardiol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.